Nasdaq Trvi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq trvi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Trvi Today - Breaking & Trending Today

Trevi Therapeutics' (TRVI) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $8.00 price target on shares of Trevi Therapeutics in […] ....

Nuveen Asset Management , Needham Company , Vanguard Group Inc , Trevi Therapeutics Inc , Trevi Therapeutics , Free Report , Street Corp , Asset Management , Get Free Report , Trevi Therapeutics Daily , Nasdaq Trvi , Reiterated Rating , Oppenheimer Holdings Inc ,

Silverarc Capital Management LLC Purchases 41,491 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Silverarc Capital Management LLC lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 927,415 shares of the company’s stock after acquiring an additional 41,491 shares during the […] ....

United States , Virtu Financial , Silverarc Capital Management , Barclays Plc , Citigroup Inc , Securities Exchange Commission , Trevi Therapeutics Inc , Trevi Therapeutics , Free Report , Capital Management , State Teachers Retirement System , Trevi Therapeutics Daily , Nasdaq Trvi , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,380,000 shares, an increase of 11.3% from the January 15th total of 1,240,000 shares. Based on an average daily volume of 387,700 shares, the days-to-cover ratio […] ....

United States , Barclays Plc , Citigroup Inc , Virtu Financial , Trevi Therapeutics Inc , Trevi Therapeutics , Get Free Report , State Teachers Retirement System , Trevi Therapeutics Daily , Nasdaq Trvi ,

Trevi Therapeutics, Inc. (NASDAQ:TRVI) to Post Q1 2024 Earnings of ($0.09) Per Share, Leerink Partnrs Forecasts

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.09) per share for the quarter. The consensus […] ....

United States , Leerink Partnrs , Vanguard Group Inc , Deutsche Bank , Trevi Therapeutics Inc , American Century Companies Inc , Sg Americas Securities , Silverarc Capital Management , Trevi Therapeutics , Free Report , Trevi Therapeutic , Get Free Report , Century Companies , Capital Management , Trevi Therapeutics Daily , Nasdaq Trvi , Earnings Estimates ,

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 0.5%

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report)’s share price traded down 0.5% during mid-day trading on Tuesday . The stock traded as low as $1.98 and last traded at $2.03. 42,249 shares were traded during mid-day trading, a decline of 75% from the average session volume of 167,613 shares. The stock had previously closed […] ....

Vr Adviser , Needham Company , Trevi Therapeutics Inc , Trevi Therapeutics Company Profile , Geode Capital Management , Vanguard Group Inc , Blackrock Inc , Trevi Therapeutics , Get Free Report , Street Corp , Capital Management , Trevi Therapeutics Daily , Nasdaq Trvi ,